Challenges and Opportunities in the Clinical Development of STING Agonists for Cancer Immunotherapy.

Motedayen Aval, Leila; Pease, James E; Sharma, Rohini; Pinato, David J

Motedayen Aval, Leila; Pease, James E; Sharma, Rohini; Pinato, David J.

Afiliación

Motedayen Aval L; Department of Surgery & Cancer, Imperial College London, Hammersmith Hospital, Du Cane Road, London W120HS, UK.
Pease JE; Inflammation, Repair & Development, National Heart & Lung Institute, Imperial College London, London SW7 2AZ, UK.
Sharma R; Department of Surgery & Cancer, Imperial College London, Hammersmith Hospital, Du Cane Road, London W120HS, UK.
Pinato DJ; Department of Surgery & Cancer, Imperial College London, Hammersmith Hospital, Du Cane Road, London W120HS, UK.

J Clin Med ; 9(10)2020 Oct 16.

Article en En | MEDLINE | ID: mdl-33081170

Palabras clave

STING; STING agonists; cGAS; cyclic dinucleotides (CDNs); drug delivery systems (DDS); immune checkpoint inhibitors (ICI); immune therapy; small molecule agonist

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google